Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)

Pfizer

Overview

Provide pre-approval single patient Expanded Access (compassionate use) of Ritlecitinib for patients.

In Expanded Access, treating physicians are the Sponsors. Expanded Access requests from treating physicians may be submitted to www.pfizercares.com. Availability will depend on location and country.

Study Type

EXPANDED_ACCESS

Conditions

Alopecia Areata

Interventions

RitlecitinibDRUG

capsules

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Must have ≥ 50% hair loss on scalp due to Alopecia Areata (AA) and be intolerant or have inadequate response to all commonly used AA therapies accessible in the country. Additional eligibility criteria may be required.

Central Contacts

Pfizer Cares

CONTACT

PfizerCares@Pfizer.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.